Item from Punto Farma
Zival Levocetirizine Dihydrochloride 2.5mg/5ml - Volume 120 ml
SKU #13626418≈ $10
Updated: 07.11.2026 02:28
The price may differ from the price on Punto Farma's website.
Important: a product from a pharmacy
We recommend taking medicines only on a doctor's prescription. TodosPy is not a seller of medicines: we only collect products and medicines from different sources and show them to you in a convenient way on one site. The final purchase, payment and delivery take place only on the pharmacy's own website or in the pharmacy itself, depending on its terms of sale and delivery.
Description
Indicaciones Indicado en la prevención y tratamiento de síndromes alérgicos cutáneos y de las vías aéreas, tales como, rinitis alérgica estacional y perenne; y para el tratamiento de la urticaria crónica idiopática. Contraindicaciones Contraindicado en pacientes con hipersensibilidad a levocetirizina, cetirizina o a cualquier componente de la formulación. Tras la administración de levocetirizina, a este tipo de pacientes podrían producírseles reacciones adversas que van desde urticaria hasta anafilaxias. No se debe administrar levocetirizina a pacientes que se encuentre en la etapa terminal de una enfermedad renal (CLCR <10 mL/min); tampoco debe administrarse a pacientes sometidos a hemodiálisis. Contraindicado en pacientes pediátricos con insuficiencia renal.
Product summary
Zival Levocetirizine Dihydrochloride 2.5mg/5ml - Volume 120 ml is a product in the “Medicines” category from the shop Punto Farma. Price: 62.000 Gs (≈ $10). Key characteristics: Brand: SIN MARCA.
Price compared with the category
The “Medicines” category has 17419 products from 5 shops: prices from 360 to 6.639.826 Gs, median price 70.579 Gs. This product costs more than 40% of the products in the category.
This product in other shops
Compared by model code. Check the contents, the warranty and the stock with the shop.
Specifications
You complete the purchase on Punto Farma's website.
Customer reviews
Nobody has reviewed this product yet.
